Integra LifeSciences Reports Second Quarter 2016 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Integra LifeSciences Reports Second Quarter 2016 Financial Results

Revenue Increased 17.2% to $249.3 million ; Organic Revenue Increased 10.7%

Reported EPS of $0.32 ; Adjusted EPS of $0.79

PLAINSBORO, N.J., July 28, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART ) today reported its financial results for the second quarter ending June 30, 2016.

Highlights:

  • Second quarter revenue increased 17.2% over the prior-year quarter to $249.3 million and organic revenue increased 10.7%;
  • GAAP gross margin was 64.1% and adjusted gross margin was 69.2%;
  • GAAP net income increased 6.1% to $12.8 million and adjusted net income increased 21.3% to $30.3 million;
  • Commercial release of Integra(R) Omnigraft(TM) Dermal Regeneration Matrix began;
  • Integra Fin-Lock(TM) Glenoid for the Titan(TM) Modular Shoulder System launched; and
  • Raising 2016 full-year sales guidance range to $992 million to $1.002 billion; Raising organic sales guidance to 9%.

Total revenues for the second quarter were $249.3 million, reflecting an increase of $36.6 million, or 17.2%, over the second quarter of 2015.  This reflects strong performance in both business segments; Orthopedics and Tissue Technologies revenue increased 38.2% and Specialty Surgical Solutions revenue increased 7.8%.

Excluding the contribution of revenues from acquisitions, discontinued products and the effect of currency exchange rates, revenues increased 10.7% over the second quarter of 2015.

"Solid performance from our two segments, as well as strength in both U.S. and international sales, contributed to the results for the second quarter," said Peter Arduini, Integra's President and Chief Executive Officer.  "We are accelerating growth as we continue to execute on our clinical and commercial strategy with the launch of several new products, including Omnigraft for the treatment of diabetic foot ulcers."

The Company reported GAAP net income of $12.8 million, or $0.32 per diluted share, for the second quarter of 2016 compared to GAAP net income of $12.0 million, or $0.35 per diluted share, for the second quarter of 2015.  Results for the second quarter of 2016 include the addition of 3.8 million shares issued in an equity offering in August 2015 and approximately 1.6 million diluted shares associated with the December 2016 convertible notes and warrants.

Adjusted measures discussed below are computed with the adjustments to GAAP reporting set forth in the attached reconciliation.

Adjusted net income for the second quarter of 2016 was $30.3 million, or $0.79 per share, compared to adjusted net income of $24.9 million, or $0.75 per share, in the second quarter of 2015. 

Adjusted EBITDA for the second quarter of 2016 was $54.6 million, or 21.9% of revenue, compared to $47.7 million, or 22.4% of revenue, in the prior year's second quarter.

Operating cash flow for the second quarter was $38.1 million.  Adjusted free cash flow conversion for the trailing twelve months ended June 30, 2016 was 59.8% versus 80.6% in the prior-year trailing twelve-month period.

The Company elected to adopt accounting standard FASB Update No. 2016-09 in the second quarter of 2016.  Excluding the benefit of this adoption, the Company's second quarter GAAP earnings per share would have been $0.30, and adjusted earnings per share would have been $0.78.  The adoption of this standard allows the Company to recognize increased tax benefits, which were previously recorded in shareholders' equity, through the income statement when employees exercise options or when shares vest.  The adoption of this standard is reflected in our results as if it had occurred at the beginning of the year.  The early adoption of this accounting standard decreased our tax expense in the second quarter of 2016 and had a GAAP net impact of $0.07 per share on a year-to-date basis.  This impact was a $0.03 benefit to adjusted earnings per share on a six-month basis, since we treat the discrete benefit as a rate item in our adjusted tax rate.  We expect that the full-year benefit to both our GAAP and adjusted results will be about $0.07 per share, although the GAAP benefit has been recognized during the first six months of the year, and the adjusted benefit will be recognized as a $0.03 benefit in the first half and approximately $0.04 in the second half of 2016.  The Company is providing a supplemental schedule on the website to show first quarter results as if the new standard had been adopted.  Access to that supplemental information is available at investor.integralife.com .

Outlook for 2016

Based on the second quarter's results, the Company is raising its full-year 2016 revenue guidance to a new range of $992 million to $1.002 billion, up from prior guidance of $985 million to $1.0 billion.  The Company is raising its full-year 2016 organic revenue growth to 9% from its previous guidance of approximately 8%.  The Company is also raising its full-year GAAP and adjusted earnings per share guidance by $0.04 per diluted share and narrowing our guidance range to a new range of $1.78 - $1.88 and $3.43 - $3.53, respectively.  This change reflects the impact from the adoption of the new accounting change, the expected additional share dilution on the 2016 convertible notes and warrants, and a slight outperformance in the second quarter results.

"In the second quarter, we continued to see positive momentum across our product portfolio, which allowed us to continue to make investments in our clinical pipeline and commercial infrastructure," said Glenn Coleman, Integra's Chief Financial Officer.  "We continue to expect margin expansion as we move through the back half of the year and are well-positioned to meet our full-year financial and strategic objectives."

In the future, the Company may record, or expects to record, certain additional revenues, gains, expenses or charges as described in the Discussion of Adjusted Financial Measures below that it will exclude in the calculation of adjusted EBITDA and adjusted earnings per share for historical periods and in providing adjusted earnings per share guidance.

Conference Call and Presentation Available Online

Integra has scheduled a conference call for 8:30 AM ET today, Thursday, July 28, 2016, to discuss financial results for the second quarter and forward-looking financial guidance.  The conference call will be hosted by Integra's senior management team and will be open to all listeners.  Additional forward-looking information may be discussed in a question and answer session following the call.

Integra's management team will reference a presentation during the conference call, which can be found on the Investor section of the website at investor.integralife.com .

Access to the live call is available by dialing (800) 723-6575 and using the passcode 9184124. The call can also be accessed through a webcast via a link provided on the Investor Relations homepage of Integra's website at investor.integralife.com .  Access to the replay is available through August 2, 2016 by dialing (719) 457-0820 and using the passcode 9184124. The webcast will also be archived on the website.

Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions and orthopedics and tissue technologies. For more information, please visit www.integralife.com .

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and reflects the Company's judgment as of the date of this release.  Forward-looking statements include, but are not limited to, statements concerning future financial performance, including projections for revenues, GAAP and Adjusted Net Income from continuing operations, GAAP and adjusted earnings from continuing operations per diluted share, non-GAAP adjustments such as global enterprise resource planning (“ERP”) system implementation charges, acquisition-related charges, impairment charges, noncash amortization of imputed interest for convertible debt, intangible asset amortization, and income tax expense (benefit) related to non-GAAP adjustments.  Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited to the Company's ability to execute its operating plan effectively, the Company's ability to obtain or manufacture and ship sufficient quantities of its products to meet its customers' demand; the ability of third-party suppliers to supply us with raw materials and finished products; global macroeconomic and political conditions; the Company's ability to manage its direct sales channels effectively; the Company's ability to maintain relationships with customers of acquired entities; physicians' willingness to adopt and third-party payors' willingness to provide reimbursement for the Company's existing, recently launched and planned products; initiatives launched by the Company's competitors; downward pricing pressures from customers; the Company's ability to secure regulatory approval for products in development; the Company's ability to remediate quality systems issues and violations; fluctuations in hospital spending for capital equipment; the Company's ability to comply with and obtain approvals for products of human origin and comply with regulations regarding products containing materials derived from animal sources; difficulties in controlling expenses, including costs to procure and manufacture raw materials and products; the impact of changes in management or staff levels; the Company's ability to integrate acquired businesses; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions; the Company's ability to leverage its existing selling organizations and administrative infrastructure; the Company's ability to increase product sales and gross margins, effectively manage inventory levels and control non-product costs; the Company’s ability to achieve anticipated growth rates, margins and scale and execute its strategy generally; the amount and timing of acquisition and integration-related costs; the geographic distribution of where the Company generates its taxable income; the effect of legislation effecting healthcare reform in the United States and internationally; fluctuations in foreign currency exchange rates; the amount of our convertible notes and bank borrowings outstanding and other factors influencing liquidity; and the economic, competitive, governmental, technological and other risk factors and uncertainties identified under the heading “Risk Factors” included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission.  These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Discussion of Adjusted Financial Measures

In addition to our GAAP results, we provide organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, adjusted diluted weighted average shares outstanding, free cash flow and adjusted free cash flow conversion.  Organic revenues consist of total revenues excluding the effects of currency exchange rates, acquired revenues and product discontinuances.  Adjusted EBITDA consists of GAAP net income from continuing operations, excluding: (i) depreciation and amortization, (ii) other income (expense), (iii) interest income and expense, (iv) income taxes, (v) and those operating expenses also excluded from adjusted net income.  The measure of adjusted net income consists of GAAP net income from continuing operations, excluding: (i) global enterprise resource planning ("ERP") implementation charges; (ii) structural optimization charges; (iii) certain employee severance charges; (iv) acquisition-related charges; (v) convertible debt noncash interest; (vi) intangible asset amortization expense; and (vii) income tax impact from adjustments and other items.  The measure of adjusted diluted weighted average shares outstanding is calculated by adding the economic benefit of the convertible note hedge transactions relating to Integra's 2016 convertible notes.  The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by adjusted diluted weighted average shares outstanding.  The measure of free cash flow consists of GAAP net cash provided by continuing operating activities from continuing operations less purchases of property and equipment.  The adjusted free cash flow conversion measure is calculated by dividing free cash flow by adjusted net income.           

Reconciliations of GAAP revenues to adjusted revenues and GAAP Adjusted Net Income from continuing operations to adjusted EBITDA, and adjusted net income, and GAAP earnings per diluted share to adjusted earnings per diluted share all for the three and six months ended June 30, 2016 and 2015, and the free cash flow and free cash flow conversion for the six months ended June 30, 2016 and 2015 and the twelve months ended June 30, 2016 and 2015, appear in the financial tables in this release.

The Company believes that the presentation of organic revenues and the various adjusted EBITDA, adjusted net income, adjusted earnings per diluted share, adjusted diluted weighted average shares outstanding, free cash flow and free cash flow conversion measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations.  For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission.  This Current Report on Form 8-K is available on the SEC's website at www.sec.gov  or on our website at www.integralife.com .

 
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
 
(UNAUDITED)
 
(In thousands, except per share amounts)
 
  Three Months Ended June 30,
  2016   2015
Total revenues, net $ 249,309     $ 212,673  
       
Costs and expenses:      
Cost of goods sold 89,565     75,251  
Research and development 14,679     12,012  
Selling, general and administrative 119,217     99,318  
Intangible asset amortization 3,471     1,747  
Total costs and expenses 226,932     188,328  
       
Operating income 22,377     24,345  
       
Interest income 6     8  
Interest expense (6,588 )   (5,485 )
Other income (expense), net (852 )   (860 )
Income from continuing operations before taxes 14,943     18,008  
Income tax expense 2,188     5,988  
Income from continuing operations 12,755     12,020  
Loss from discontinued operations, (net of tax expense benefit) $ —     $ (7,022 )
Net income $ 12,755     $ 4,998  
       
Net income per share:      
Income from continuing operations $ 0.32     $ 0.35  
Loss from discontinued operations —     (0.21 )
Net income per share $ 0.32     $ 0.14  
       
Weighted average common shares outstanding for diluted net income per share 39,355     33,939  
           

Segment revenues and growth in total revenues excluding the effects of currency exchange rates, acquisitions and discontinued products are as follows:

(In thousands)  
   
  Three Months Ended June 30,
    2016     2015   Change
Specialty Surgical Solutions $ 158,163   $ 146,709     8 %
Orthopedics and Tissue Technologies   91,146     65,964     38 %
Total revenue $ 249,309   $ 212,673     17 %
       
Impact of changes in currency exchange rates $ (39 ) $ —    
Less contribution of revenues from acquisitions *   (16,965 )   —    
Less contribution of revenues from discontinued products   (1,805 )   (4,462 )   (60 )%
Total organic revenues $ 230,500   $ 208,211     10.7 %
       
* Acquisitions include TEI, Salto and Tekmed.      
       

Items included in GAAP net income from continuing operations and location where each item is recorded are as follows:

(In thousands)
 
Three Months Ended June 30, 2016
 
Item Total Amount COGS(a) SG&A(b) Amort.(c) OI&E(d) Tax(e)
Global ERP implementation charges $ 5,696   $ —   $ 5,696   $ —   $ —   $ —  
Structural optimization charges   1,838     1,008     830     —     —     —  
Acquisition-related charges   6,020     4,644     1,376     —     —     —  
Certain employee severance charges   617     317     300     —     —     —  
Intangible asset amortization expense   10,351     6,880     —     3,471     —     —  
Convertible debt noncash interest   2,104     —     —     —     2,104     —  
Estimated income tax impact from above adjustments and other items   (9,120 )   —     —     —     —     (9,120 )
Total Adjustments $ 17,506   $ 12,849   $ 8,202   $ 3,471   $ 2,104   $ (9,120 )
             
Depreciation expense   7,663     —     —     —     —     —  
                 

a)  COGS - Cost of goods sold b)  SG&A - Selling, general and administrative c)  Amort. - Intangible asset amortization d)  OI&E - Interest (income) expense, net and other (income) expense, net e)  Tax - Income tax expense

 

Three Months Ended June 30, 2015
 
(In thousands)
 
Item Total Amount COGS (a) SG&A (b) Amort. (c) OI&E (d) Tax (e)
Global ERP implementation charges $ 3,610   $ —   $ 3,610   $ —   $ —   $ —  
Structural optimization charges   3,641     2,047     1,594     —       —  
Acquisition-related charges   3,334     587     2,747     —     —     —  
Certain employee severance charges   253     —     253     —     —     —  
Intangible asset amortization expense   5,992     4,245     —     1,747     —     —  
Convertible debt noncash interest   1,885     —     —     —     1,885     —  
Estimated income tax impact from above adjustments and other items   (5,796 )   —     —     —     —     (5,796 )
Total Adjustments $ 12,919   $ 6,879   $ 8,204   $ 1,747   $ 1,885   $ (5,796 )
             
Depreciation expense   6,548     —     —     —     —     —  
                                     

a)  COGS - Cost of goods sold b)  SG&A - Selling, general and administrative c)  Amort. - Intangible asset amortization d)  OI&E - Interest (income) expense, net and other (income) expense, net e)  Tax - Income tax expense

 

RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME FROM CONTINUING OPERATIONS TO ADJUSTED EBITDA
(UNAUDITED)
(In thousands, except per share amounts)
 
  Three Months Ended June 30,
  2016   2015
       
GAAP net income from continuing operations $ 12,755     $ 12,020  
Non-GAAP adjustments:      
Depreciation and intangible asset amortization expense 18,014     12,541  
Other (income) expense, net 852     860  
Interest expense, net 6,582     5,477  
Income tax expense 2,188     5,988  
Global ERP implementation charges 5,696     3,610  
Structural optimization charges 1,838     3,641  
Acquisition-related charges 6,020     3,334  
Certain employee severance charges 617     253  
       
Total of non-GAAP adjustments 41,807     35,704  
Adjusted EBITDA $ 54,562     $ 47,724  
       

 

RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME FROM CONTINUING OPERATIONS TO MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE
(UNAUDITED)
(In thousands, except per share amounts)
 
  Three Months Ended June 30,
  2016   2015
       
GAAP net income from continuing operations $ 12,755     $ 12,020  
Non-GAAP adjustments:      
Global ERP implementation charges 5,696     3,610  
Structural optimization charges 1,838     3,641  
Acquisition-related charges 6,020     3,334  
Certain employee severance charges 617     253  
Intangible asset amortization expense 10,351     5,992  
Convertible debt noncash interest 2,104     1,885  
Estimated income tax impact from adjustments and other items (9,120 )   (5,796 )
       
Total of non-GAAP adjustments 17,506     12,919  
Adjusted net income $ 30,261     $ 24,939  
       
Adjusted diluted net income per share $ 0.79     $ 0.75  
 
Weighted average common shares outstanding for diluted net income per share        39,355      33,939
       
Weighted average common shares outstanding adjustment for economic benefit of convertible bond hedge transactions (1,142 )   (477 )
Weighted average common shares outstanding for adjusted diluted net income per share 38,213     33,462  
           

 

CONDENSED BALANCE SHEET DATA
(UNAUDITED)
   
(In thousands)  
  June 30,   December 31, 
2016   2015  
       
Cash and cash equivalents $ 86,803     $ 48,132  
Accounts receivable, net 145,571     132,241  
Inventories, net 220,442     211,429  
       
Bank line of credit 482,500     496,250  
Convertible securities 223,041     218,240  
       
Stockholders' equity 794,787     751,443  
   
   
CONDENSED STATEMENT OF CASH FLOWS
(UNAUDITED)
   
(In thousands)  
   
  Six Months Ended June 30,
   
  2016   2015
Net cash provided by operating activities $ 63,109     $ 59,603  
Net cash used in investing activities (14,773 )   (18,744 )
Net cash (used in) provided by financing activities (9,082 )   20,590  
Effect of exchange rate changes on cash and cash equivalents (583 )   (2,146 )
       
Net increase in cash and cash equivalents 38,671     59,303  
       
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP OPERATING CASH FLOW TO
MEASURES OF FREE CASH FLOW AND FREE CASH FLOW CONVERSION
(UNAUDITED)
(In thousands)  
  Three Months Ended June 30,
  2016 2015
GAAP Net cash provided by continuing operating activities $ 38,079   $ 42,509  
     
     
Purchases of property and equipment from continuing operations (8,267 ) (9,623 )
Free Cash Flow 29,812   32,886  
     
Adjusted net income * $ 30,261   $ 24,939  
Adjusted Free Cash Flow Conversion 98.5 % 131.9 %
     
     
     
  Twelve Months Ended June 30,
  2016 2015
GAAP Net cash provided by continuing operating activities $ 108,362   $ 117,068  
     
Purchases of property and equipment from continuing operations (37,622 ) (34,172 )
Free Cash Flow 70,740   82,896  
     
Adjusted net income * $ 118,243   $ 102,894  
Adjusted Free Cash Flow Conversion 59.8 % 80.6 %
     

* Adjusted net income for quarters ended June 30, 2016 and 2015 are reconciled above.  Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations and the Historical Financial Results: Continuing Operations presentation on our website investor.integralife.com  under Events & Presentations.

The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income.  The Company believes this measure is a useful metric in evaluating the significance of the cash special charges in its adjusted earnings measures.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION  
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GUIDANCE  
   
   
             
  Recorded Year to Date   Projected Year Ended  
         
(In thousands, except per share amounts) June 30, 2016   December 31, 2016  
      Low   High  
GAAP net income $ 26,173     $ 70,533     $ 74,433    
Non-GAAP adjustments:            
Global ERP implementation charges 9,020     15,000     15,000    
Structural optimization charges 3,547     11,500     11,500    
Acquisition-related charges 12,061     18,000     18,000    
Certain employee severance charges 1,267     1,267     1,267    
Intangible asset amortization expense 20,888     42,000     42,000    
Convertible debt non-cash interest 4,168     8,200     8,200    
Estimated income tax impact from adjustments and other items (18,600 )   (34,000 )   (34,000 )  
             
Total of non-GAAP adjustments 32,351     61,967     61,967    
Adjusted net income $ 58,524     $ 132,500     $ 136,400    
             
GAAP diluted net income per share $ 0.68     $ 1.78     $ 1.88    
Non-GAAP adjustments detailed above (per share) $ 0.87     $ 1.65     $ 1.65    
Adjusted diluted net income per share $ 1.55     $ 3.43     $ 3.53    
             
Weighted average common shares outstanding for diluted net income per share 38,771     39,600     39,600    
Weighted average common shares outstanding adjustment for convertible dilution (898 )   (1,000 )   (1,000 )  
Weighted average common shares outstanding for adjusted diluted net income per share 37,873     38,600     38,600    
                   
GUIDANCE - SPECIAL CHARGES
                   

 

Item YTD Amount FY Guidance COGS SG&A Amort. Interest (Inc)Exp Tax
Global ERP implementation charges $ 9,020   $ 15,000   $ —   $ 15,000   $ —   $ —   $ —  
Structural optimization charges 3,547   11,500   6,000   5,500   —      
Acquisition-related charges 12,061   18,000   14,000   4,000   —   —   —  
Certain employee severance charges 1,267   1,267     1,267   —   —   —  
Intangible asset amortization expense 20,888   42,000   28,000   —   14,000   —   —  
Convertible debt non-cash interest 4,168   8,200   —   —   —   8,200   —  
Estimated income tax impact from adjustments and other items (18,600 ) (34,000 ) —   —   —   —   (34,000 )
Total 32,351   61,967   48,000   25,767   14,000   8,200   (34,000 )
   

Contact: Investor Relations: Angela Steinway (609) 936-2268 angela.steinway@integralife.com Michael Beaulieu (609) 750-2827 michael.beaulieu@integralife.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 43

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 49

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 87

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 12

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 34

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 55

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 53

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 54

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
KuCoin Unveils $1.1M USDT Black Friday Bonanza

Updated Category News Views 31

KuCoin's Festive Fireworks: Black Friday Bonanza Sometimes the crypto world feels like a carnival, and KuCoin's latest act is the $1.1 million USDT prize pool, rolling out as part of its 'Tis The Season holiday campaign. A move that matches the glitz of Tomorrowland Winter experiences, adding more sparkle to the crypto stage. Behind the Scenes of the KuCoin-Tomorrowland...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 41

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Join the Challenge: Investors Pursue Justice Against TLX

Updated Category News Views 164

Opportunity for Investors in Telix Pharmaceuticals Ltd. Attention, investors! A significant event has unfolded for those who have purchased securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). The Rosen Law Firm, well-known for representing investors' rights, has initiated a class action lawsuit on behalf of these investors. This development presents a chance for you...

Continue Reading
Turvo and SMC3 Forge Alliance to Enhance Freight Efficiency

Updated Category News Views 158

Strategic Partnership Between Turvo and SMC3 Industry leaders are joining forces to enhance freight management solutions, facilitated by insights from a global logistics company. Turvo, known for its collaborative application tailored for the supply chain, has announced an integration partnership with SMC3, a respected provider of less-than-truckload (LTL) freight...

Continue Reading
Fnac Darty Takes Major Steps in Unieuro Acquisition Process

Updated Category News Views 148

Fnac Darty Makes Progress in Unieuro Acquisition Fnac Darty has recently announced significant developments regarding its acquisition of Unieuro. The authorization to officially notify this transaction was granted by the European Commission, following a pre-notification phase that lasted several months. This is an exciting development for shareholders and has set the...

Continue Reading
LOGISTEC Appoints Cleidy Liborio Fernandes as CCO for Growth

Updated Category News Views 202

CLEIDY LIBORIO FERNANDES JOINS LOGISTEC AS CHIEF COMMERCIAL OFFICER LOGISTEC, a prominent provider of marine and environmental services in North America, is delighted to announce the appointment of Cleidy Liborio Fernandes as the new Chief Commercial Officer. Cleidy's extensive background in international business and strategic development is expected to spearhead the...

Continue Reading
IMUNON Inc's Latest Developments Drive Stock Surge Today

Updated Category News Views 233

IMUNON Inc's Stock Surge Explained Shares of IMUNON Inc (NASDAQ: IMNN) are seeing a remarkable uptick in trading this Wednesday. The excitement is largely due to the company achieving a significant clinical milestone for its lead drug candidate, IMNN-001. This news has generated substantial interest among investors and highlights IMUNON's progress in the pharmaceutical...

Continue Reading